about
Cardiovascular safety of anti-diabetic drugsMolecular action of sulphonylureas on KATP channels: a real partnership between drugs and nucleotidesPlace of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementA Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic AgenIsoenergetic Polymorphism: The Puzzle of Tolazamide as a Case Study.Bioactive PeptidesModelling endogenous insulin concentration in type 2 diabetes during closed-loop insulin delivery.GLP-1 based therapeutics: simultaneously combating T2DM and obesity.Xenopus as a Model for GI/Pancreas Disease.Metformin treatment status and abdominal aortic aneurysm disease progression.Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.Emerging treatments for post-transplantation diabetes mellitus.Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors.Investigational insulin secretagogues for type 2 diabetes.Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.Sulfonylurea: Personalized Medicine for Type 2 Diabetes.Hypoglycemia Secondary to Sulfonylurea Ingestion in a Patient with End Stage Renal Disease: Results from a 72-Hour Fast.Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.Modern Sulfonylureas Strike Back - Exploring the Freedom of FlexibilityDevelopment of value-added nutritious crackers with high antidiabetic properties from blends of () and blanched Pigeon pea ()Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysisOverview of Cellular Transplantation in Diabetes Mellitus: Focus on the Metabolic Outcome
P2860
Q26741082-595AFC36-01AF-4F95-BF8F-DC264183ABD8Q26777728-AAB6895E-32E5-424A-B6CA-D3FDB580A2A6Q26783199-5C6B5209-0AAF-4FE4-9E57-A55FFF0EE487Q28552837-911752DA-FFA2-4266-9048-D2C54F669790Q33361425-21F16376-9964-44F4-9CEE-72F647352BF2Q33737179-46C78F7C-5306-4CB0-83EA-F215D00D9FDFQ35176744-D181B7A0-F84E-4665-9461-376545859C83Q35200252-67FA86B5-CED7-4BD5-AE95-C7DA64F0C307Q35899895-42AEDCB3-B89C-4F68-A196-91FE8EBA324BQ37047861-EB998B0A-1D26-400C-B587-1C39CAC10719Q38364806-07719210-569C-4E5C-AA47-42B46215A019Q38445269-F63E967B-D974-468D-9DEA-9AD1E658F80EQ38697458-8118C49E-842F-4BD4-8FD4-E6DF6D446F73Q38735419-35656AE8-1C14-41BA-93C6-1E73A733B7A3Q38789945-F077CDC2-821B-4089-9243-7BEBD191D67EQ38845574-07C24A65-1DD2-4BD7-9707-18178C2C5DCDQ42929953-E0AD11E9-DA74-4E7B-ACFA-9DF2B8F18F46Q43148717-752CA308-4EC1-477C-92FD-939C8FC24235Q47871565-BBC8932D-5ECC-473B-89DE-8AB011E75EA2Q52657004-F0B63866-263B-4BAC-AD33-FB768C8782BFQ57822737-F9AFC120-9D2B-4728-9C55-938C505CA4D9Q57824073-9DF659F0-0D5E-4367-9D0F-0AE239E2D2D2Q58701706-4798CEE8-B3E3-4CB0-B325-EFC52BCD04CDQ59101873-555523E9-3561-4EC0-BCFB-E0227657D264
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sulfonylureas: a new look at old therapy.
@en
type
label
Sulfonylureas: a new look at old therapy.
@en
prefLabel
Sulfonylureas: a new look at old therapy.
@en
P2860
P1476
Sulfonylureas: a new look at old therapy.
@en
P2093
Guillermo Umpierrez
Peter M Thulé
P2860
P2888
P356
10.1007/S11892-014-0473-5
P577
2014-04-01T00:00:00Z
P6179
1036360434